Literature DB >> 16483454

Falls in Parkinson's disease. Causes and impact on patients' quality of life.

Małgorzata Michałowska1, Urszula Fiszer, Anna Krygowska-Wajs, Krzysztof Owczarek.   

Abstract

The aim of this study was to investigate the prevalence of the different causes of falling in Parkinson's disease (PD) and to evaluate the influence of falls on patients' quality of life (QoL). We recruited 60 PD patients (31 with falls, 29 without falls). We found that falls were caused by: unstable posture (29.0%), freezing or festination (25.8%), sudden loss of postural reflexes (toppling falls) (25.8%), co-existing neurological disorders (6.5%), cardiological disorders (6.5%), and symptomatic orthostatic hypotension (3.2%). Duration of the disease was longer, its stage more advanced, daily levodopa dosage higher, and the proportion of patients with abnormalities in the EEG apparently greater in the group with falls. The presence of falls was found to be a factor contributing to a multidirectional negative impact on patients' QoL. QoL also depended on impairment of cognitive function, daily dosage of levodopa, disease duration, disease progression, and sex. The results of this study underline the need to diagnose the causes of falls in order to institute appropriate treatment and to improve patients' QoL.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16483454

Source DB:  PubMed          Journal:  Funct Neurol        ISSN: 0393-5264


  31 in total

1.  Postural instability/gait disturbance in Parkinson's disease has distinct subtypes: an exploratory analysis.

Authors:  Stewart A Factor; N Kyle Steenland; Donald S Higgins; Eric S Molho; Denise M Kay; Jennifer Montimurro; Ami R Rosen; Cyrus P Zabetian; Haydeh Payami
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-09-30       Impact factor: 10.154

2.  Progression of postural changes in Parkinson's disease: quantitative assessment.

Authors:  Alexander Khlebtovsky; Ruth Djaldetti; Yaniv Rodity; Ofir Keret; Gloria Tsvetov; Ilana Slutzcki-Shraga; Felix Benninger
Journal:  J Neurol       Date:  2017-02-02       Impact factor: 4.849

3.  Effects of physical activity in Parkinson's disease: A new tool for rehabilitation.

Authors:  Paolo Borrione; Eliana Tranchita; Pierpaolo Sansone; Attilio Parisi
Journal:  World J Methodol       Date:  2014-09-26

4.  Falls in ambulatory non-demented patients with Parkinson's disease.

Authors:  Olivier Rascol; Santiago Perez-Lloret; Philippe Damier; Arnaud Delval; Pascal Derkinderen; Alain Destée; Wassilios G Meissner; Francois Tison; Laurence Negre-Pages
Journal:  J Neural Transm (Vienna)       Date:  2015-04-07       Impact factor: 3.575

Review 5.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

6.  Treadmill gait training improves baroreflex sensitivity in Parkinson's disease.

Authors:  Mohan Ganesan; Pramod Kumar Pal; Anupam Gupta; Talakad N Sathyaprabha
Journal:  Clin Auton Res       Date:  2014-06       Impact factor: 4.435

7.  Assessment of fall-related self-efficacy and activity avoidance in people with Parkinson's disease.

Authors:  Maria H Nilsson; Anna-Maria Drake; Peter Hagell
Journal:  BMC Geriatr       Date:  2010-10-25       Impact factor: 3.921

8.  Determinants of health-related quality of life in people with Parkinson's disease: a path analysis.

Authors:  Sze-Ee Soh; Jennifer L McGinley; Jennifer J Watts; Robert Iansek; Anna T Murphy; Hylton B Menz; Frances Huxham; Meg E Morris
Journal:  Qual Life Res       Date:  2012-10-16       Impact factor: 4.147

9.  [Freezing of gait : phenomenology, pathophysiology, and therapeutic approaches].

Authors:  F Schroeteler; K Ziegler; U M Fietzek; A Ceballos-Baumann
Journal:  Nervenarzt       Date:  2009-06       Impact factor: 1.214

Review 10.  Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease.

Authors:  David A Gallagher; Anette Schrag
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.